EcoDrugPlus

Aurora Kinase A Pseudogene

Ensembl ID : ENSANAG00000035687
Gene Symbol: LOC105728530
1 Cross references
232 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Aurora Kinase B

Ensembl ID : ENSANAG00000035885
Gene Symbol: AURKB
4 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Aurora Kinase C

Ensembl ID : ENSANAG00000031881
Gene Symbol: AURKC
4 Cross references
99 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Beta-Secretase 1

Ensembl ID : ENSANAG00000027782
Gene Symbol: BACE1
4 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bradykinin Receptor B1

Ensembl ID : ENSANAG00000035294
Gene Symbol: BDKRB1
2 Cross references
149 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bradykinin Receptor B2

Ensembl ID : ENSANAG00000025714
Gene Symbol: BDKRB2
4 Cross references
362 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Butyrylcholinesterase

Ensembl ID : ENSANAG00000019984
Gene Symbol: BCHE
4 Cross references
130 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Camp And Camp-Inhibited Cgmp 3',5'-Cyclic Phosphodiesterase 10a Pseudogene

Ensembl ID : ENSANAG00000006352
Gene Symbol: LOC105707816
1 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Camp-Dependent Protein Kinase Catalytic Subunit Gamma-Like

Ensembl ID : ENSANAG00000031041
Gene Symbol: LOC105731947
2 Cross references
361 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcitonin Receptor Like Receptor

Ensembl ID : ENSANAG00000025809
Gene Symbol: CALCRL
4 Cross references
149 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Sensing Receptor

Ensembl ID : ENSANAG00000032020
Gene Symbol: CASR
4 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSANAG00000036416
Gene Symbol: CACNA2D1
4 Cross references
287 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).